Clene Inc. (NasdaqCM: CLNN)
Health Care · Biotechnology · US
$3.10
-19.69% today · -62.0% 1Y
Clene Inc. (NasdaqCM: CLNN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $44.06M and employs 78 people.
Over the last twelve months the share price has lost 62.0%, trading between 3.02 and 13.50.
Tweenvest scores Clene Inc. across four factors: quality 22/100, value 40/100, growth 0/100. Its strongest factor is value.
CLNN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $44.06M
- Revenue (TTM)
- $197.00K
- P/E
- —
- EPS
- -3.50
- Dividend yield
- —
- Beta (5Y)
- 0.92
- 52-week high
- $13.50
- 52-week low
- $3.02
- Avg volume (3M)
- —
- Shares outstanding
- 14.21M
- Employees
- 78
- Next earnings
- —
About Clene Inc.
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
- ISIN
- US1856342019
- Listed since
- Oct 18, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Mereo BioPharma Group plcNasdaqCM: MREO | $45.90M | $0.29 | -1.30% |
| ImageneBio, Inc.NasdaqCM: IMA | $45.86M | $4.04 | -4.72% |
| Harvard Apparatus Regenerative Technology Inc.OTCPK: HRGN | $45.23M | $2.23 | -3.04% |
| GenMont Biotech IncorporationTWSE: 3164 | $44.54M | NT$16.80 | -0.88% |
| Serina Therapeutics, Inc.NYSEAM: SER | $43.69M | $1.72 | -14.00% |
| CapForce Inc.OTCPK: CFOR | $43.39M | $3.50 | -12.37% |
| ABION Inc.KOSDAQ: A203400 | $43.09M | ₩— | — |
| Psomagen, Inc.KOSDAQ: A950200 | $42.85M | ₩2,970.00 | -0.17% |
Figures last refreshed Oct 18, 2026.